Synlett 2016; 27(17): 2447-2450
DOI: 10.1055/s-0035-1562454
letter
© Georg Thieme Verlag Stuttgart · New York

An Improved Synthesis of CENTA, a Chromogenic Substrate for β-Lactamases

Antonio Quotadamo
a   TYDOCK PHARMA S.r.l., Strada Gherbella 294/b, Modena, 41126, Italy   Email: a.venturelli@tydockpharma.com
,
Pasquale Linciano
b   Dipartimento di Scienze della Vita, Università degli Studi di Modena e Reggio Emilia, Via Campi 103, 41125 Modena, Italy
,
Paolo Davoli
b   Dipartimento di Scienze della Vita, Università degli Studi di Modena e Reggio Emilia, Via Campi 103, 41125 Modena, Italy
,
Donatella Tondi
b   Dipartimento di Scienze della Vita, Università degli Studi di Modena e Reggio Emilia, Via Campi 103, 41125 Modena, Italy
,
Maria Paola Costi*
b   Dipartimento di Scienze della Vita, Università degli Studi di Modena e Reggio Emilia, Via Campi 103, 41125 Modena, Italy
,
Alberto Venturelli*
a   TYDOCK PHARMA S.r.l., Strada Gherbella 294/b, Modena, 41126, Italy   Email: a.venturelli@tydockpharma.com
› Author Affiliations
Further Information

Publication History

Received: 14 April 2016

Accepted after revision: 31 May 2016

Publication Date:
07 July 2016 (online)


Abstract

7-β-Thien-2-yl-acetamido-3-[(4-nitro-3-carboxyphenyl)thiomethyl]-3-cephem-4-carboxylic acid (CENTA) is a yellow chromogenic β-lactamases (BL) substrate. It hydrolyses readily in the presence of all BL and is therefore suitable for kinetic studies, the detection of BL enzymes in crude extracts and chromatographic fractions. CENTA is commercially available at a high price because of the cumbersome synthetic protocol, the only currently available for its preparation. Here we describe a new efficient and improved process for the preparation of CENTA. Starting from the easily available 7-aminocephalosporanic acid (7-ACA) through a three-step synthesis, CENTA was obtained with a 75% overall yield. The newly developed process proceeds through a pivotal intermediate in cephalosporin chemistry, which may be used as starting compound for the development of new cephalosporin derivatives.

Supporting Information

 
  • References and Notes

  • 1 Livermore DM, Brown DF. J. Antimicrob. Chemother. 2001; 48: 59; Suppl. 1
  • 2 van Berkel SS, Brem J, Rydzik AM, Salimraj R, Cain R, Verma A, Owens RJ, Fishwick CW. G, Spencer J, Schofield CJ. J. Med. Chem. 2013; 56: 6945
  • 3 Bidya S, Suman R. Open J. Clin. Diagn. 2014; 4: 47
  • 4 Montgomery K, Raymundo L, Drew WL. J. Clin. Microbiol. 1979; 9: 205
  • 5 Papanicolaou GA, Medeiros AA. Antimicrob. Agents Chemother. 1990; 34: 2184
  • 6 Kobayashi S, Arai S, Hayashi S, Sakaguchi T. Antimicrob. Agents Chemother. 1988; 32: 1040
    • 7a O'Callaghan CH, Morris A, Kirby SM, Shingler AH. Antimicrob. Agents Chemother. 1972; 1: 283
    • 7b http://www.merckmillipore.com/FR/fr/product/Nitrocefin---CAS-41906-86-9---Calbiochem,EMD_BIO-484400?bd=1.
  • 8 Pitkälä A, Salmikivi L, Bredbacka P, Myllyniemi A.-L, Koskinen MT. J. Clin. Microbiol. 2007; 45: 2031
  • 9 Marshall SA, Sutton LD, Jones RN. Diagn. Microbiol. Infect. Dis. 1995; 22: 353
  • 10 Uri JV. Acta Microbiol. Hung. 1985; 32: 133
    • 11a Bebrone C, Moali C, Mahy F, Rival S, Docquier JD, Rossolini GM, Fastrez J, Pratt RF, Frere JM, Galleni M. Antimicrob. Agents Chemother. 2001; 45: 1868
    • 11b http://www.merckmillipore.com/FR/fr/product/CENTA%E2%84%A2-%CE%B2-Lactamase-Substrate---CAS-9073-60-3---Calbiochem,EMD_BIO-219475.
  • 12 Morin S, Clouthier CM, Gobeil S, Pelletier JN, Gagne SM. Biomol. NMR Assignments 2010; 4: 127
  • 13 Padiolleau-Lefevre S, Debat H, Thomas D, Friboulet A, Avalle B. Biocatal. Biotransform. 2003; 21: 79
  • 14 Hugonnet J.-E, Blanchard JS. Biochemistry 2007; 46: 11998
  • 15 Mandal S, Maharjan M, Ganguly S, Chatterjee M, Singh S, Buckner FS, Madhubala R. Indian J. Exp. Biol. 2009; 47: 475
  • 16 Yang-Woytowitz M, Yu C, Wiles T. WO 2009051838 A1, 2009
  • 17 Bebrone C, Anne C, De Vriendt K, Devreese B, Rossolini GM, Van Beeumen J, Frere JM, Galleni M. J. Biol. Chem. 2005; 280: 28195
  • 18 Page MG. P. Biochim. Biophys. Acta 1994; 1205: 199
  • 19 Vella P, Hussein WM, Leung EW. W, Clayton D, Ollis DL, Mitić N, Schenk G, McGeary RP. Bioorg. Med. Chem. Lett. 2011; 21: 3282
  • 20 Perumal SK, Pratt RF. J. Org. Chem. 2006; 71: 4778
  • 21 Makena A, van Berkel SS, Lejeune C, Owens RJ, Verma A, Salimraj R, Spencer J, Brem J, Schofield CJ. ChemMedChem 2013; 8: 1923
  • 22 Hailu TT, Foit L, Bardwell JC. A. Anal. Biochem. 2013; 434: 181
  • 23 Kristiansen A, Grgic M, Altermark B, Leiros I. J. Antimicrob. Chemother. 2015; 70: 766
  • 24 Jones RN, Wilson HW, Novick WJ, Barry AL, Thornsberry C. J. Clin. Microbiol. 1982; 15: 954
  • 25 5-Mercapto-2-nitrobenzoic Acid (TNB, 1) In a 50 mL one-neck round-bottom flask, 5,5′-dithiobis(2-nitrobenzoic acid) (420 mg, 1.06 mmol, 1 equiv) was slurried in 80% EtOH (v/v, 5 mL) cooled to 0 °C with an ice bath. NaBH4 (320 mg, 8.46 mmol, 8 equiv) was dissolved in distilled water (2 mL) and slowly added dropwise through an addition funnel (CAUTION! Vigorous effervescence develops!). The resulting dark red mixture was stirred at r.t. until gas evolution subsided. After dilution with EtOH (5 mL) and distilled water (5 mL), the mixture was acidified with 2 N HCl, extracted with CH2Cl2 (3 × 20 mL), and the pooled organic layers were washed with distilled water (3 × 50 mL) and brine (3 × 50 mL). The yellow organic solution was dried over Na2SO4, filtered, and concentrated to dryness to afford the desired thiol as a bright orange solid (410 mg, 97% yield); mp 143–145 °C. 1H NMR (400 MHz, CDCl3): δ = 3.84 (1 H, s, SH), 5.77 (1 H, br, COOH), 7.48 (1 H, dd, J = 8.5, 2.1 Hz, H-4), 7.63 (1 H, d, J = 2.1 Hz, H-6), 7.86 (1 H, d, J = 8.5 Hz, H-3). 13C NMR (100 MHz, CDCl3): δ = 125.2 (C-3), 126.6 (C-1), 128.8 (C-6), 128.9 (C-4), 141.6 (C-5), 146.5 (C-2), 165.3 (COOH). MS: m/z = 200.1 [M + H]+; 198.0 [M – H]. Anal. Calcd for C7H5NO4S: C, 42.21; H, 2.53; N, 7.03. Found: C, 42.19; H, 2.55; N, 7.07.
  • 26 (6R,7R)-7-Amino-3-{[(3-carboxy-4-nitrophenyl)thio]-methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid (2) 7-Aminocephalosporanic acid (7-ACA, 0.547 g, 2.01 mmol, 1 equiv) and 5-mercapto-2-nitrobenzoic acid (1, 0.400 g, 2.01 mmol, 1 equiv) were successively added to a stirred solution of BF3 (1 M solution in THF, 6.03 mL, 6.03 mmol, 3 equiv) in 40 mL anhydrous MeCN, and the resulting solution was stirred at r.t. for 2 h. After cooling in an ice-bath, the mixture was diluted with water (50 mL) and adjusted to pH 4.0 by addition of 28% NH4OH. The resulting ochre-yellow precipitate was collected by filtration and washed with water and acetone to afford the title compound as a light ochre powder (0.768 g, 93%); mp 184 °C (dec.); [α]D 25 = –26.4 (1.07% w/v in DMSO). 1H NMR (400 MHz, DMSO-d 6): δ = 3.49 (1 H, d, J = 17.8 Hz, H-4), 3.69 (1 H, d, J = 17.8 Hz, H-4), 4.16 (1 H, d, J = 12.8 Hz, CH2–C-3), 4.29 (1 H, d, J = 12.8 Hz, CH2–C-3), 4.77 (1 H, d, J = 5.0 Hz, H-7), 4.98 (1 H, d, J = 5.0 Hz, H-6), 7.62 (1 H, dd, J = 8.6, 1.9 Hz, H-6′), 7.66 (1 H, d, J = 1.9 Hz, H-2′), 7.93 (1 H, d, J = 8.6 Hz, H-5′). 13C NMR (100 MHz, DMSO-d 6): δ = 27.2 (C-4), 35.2 (CH2–C-3), 59.4 (C-6), 63.5 (C-7), 124.5 (C-3)*, 125.0 (C-5´), 126.8 (C-2)*, 128.0 (C-2′), 130.2 (C-6′), 144.7 (C-1′), 145.1 (C-4′), 163.8 (C-2–COOH), 166.4 (C-3′–COOH), 169.4 (C-8) [* assignments may be interchangeable]. MS: m/z = 412.1 [M + H]+; 410.0 [M – H]. Anal. Calcd for C15H13N3O7S2: C, 43.79; H, 3.18; N, 10.21. Found: C, 43.76; H, 3.17; N, 10.24.
  • 27 Saikawa I, Takano S, Momonoi K, Takakura I, Tanaka K, Kutani C. Chem. Pharm. Bull. 1985; 33: 5534

    • (6R,7R)-3-{[(3-Carboxy-4-nitrophenyl)thio]methyl}-8-oxo-7-]2-(thiophen-2-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (CENTA, 3)
    • 28a Method c A solution of potassium trimethylsilanolate (0.218 g, 1.7 mmol, 2 equiv) and 2-thienylacetyl chloride (0.136 g, 0.850 mmol, 1 equiv) in anhydrous MeCN (10 mL) was added simultaneously to a suspension of 2 (0.35 g, 0.850 mmol, 1 equiv) in anhydrous CH2Cl2 (30 mL) at 0 °C over 0.5 h. The resulting mixture was stirred at r.t. for 1 h and then heated at 50 °C for 2 h. After evaporation of the solvent under reduced pressure, the residue was taken up with 10 mL of distilled water, acidified to pH 2.0 with 1 M HCl, and extracted with EtOAc (3 × 15 mL). The pooled organic layers were washed with water (3 × 50 mL) and brine (3 × 50 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was recrystallized from MeOH–Et2O to give the desired compound in undissociated form as a yellow solid (0.377 g, 0.705 mmol, 83% yield with respect to 2)
    • 28b Method d In a 50 mL round-bottom flask, compound 2 (0.35 g, 0.850 mmol, 1 equiv) and 2-(thiophen-2-yl)acetic acid (0.120 g, 0.850 mmol, 1 equiv) were dissolved in anhydrous DMF (5 mL) at 0 °C under nitrogen atmosphere. A solution of EDC·HCl (0.180 g, 0.935 mmol, 1.1 equiv) in DMF (5 mL) was added dropwise at 0 °C, and the mixture was allowed to warm gradually and left to stir at r.t. for 6 h. The solvent was then concentrated in vacuo, and water (20 mL) was added. The resulting aqueous phase was extracted with EtOAc (3 × 20 mL) and the pooled organic layers washed with water (3 × 50 mL), brine (3 × 50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. Subsequently, the dry residue was dissolved in 25 mL of water containing 1 equiv of NaHCO3. The solution was filtered through a Sephadex G-10 column and freeze-dried to afford the sodium salt of the title compound as a light brown solid (0.327 g, 73% yield with respect to 2); mp 59.3–62.2 °C. 1H NMR (400 MHz, DMSO-d 6): δ = 3.54 (1 H, d, J = 18.0 Hz, H-4), 3.73 (1 H, d, J = 18.0 Hz, H-4), 3.76 (2 H, AB system, CH2–C-2′), 4.26 (2 H, s, CH2–C-3), 5.12 (1 H, d, J = 4.8 Hz, H-6), 5.66 (1 H, dd, J = 4.8, 8.3 Hz, H-7), 6.93 (1 H, m, H-3′), 6.95 (1 H, d, J = 5.0 Hz, H-4′), 7.36 (1 H, dd, J = 1.2, 5.0 Hz, H-5′), 7.66 (1 H, dd, J = 2.1, 8.6 Hz, H-6′′), 7.70 (1 H, d, J = 2.1 Hz, H-2′′), 7.96 (1 H, d, J = 8.6 Hz, H-5′′), 9.12 (1 H, d, J = 8.3 Hz, NH–C-7), 13.7–13.8 (2 H, br, 2 × COOH). 13C NMR (100 MHz, DMSO-d 6): δ = 27.6 (C-4), 35.1 (CH2–C-3), 36.2 (CH2–C-2′), 58.2 (C-6), 59.6 (C-7), 125.0 (C-5′′), 125.4 (C-5′), 126.1 (C-2)*, 126.3 (C-3)*, 126.8 (C-3′), 127.1 (C-4′), 128.0 (C-2′′), 129.5 (C-3′′), 130.2 (C-6′′), 137.3 (C-2′), 144.9 (C-1′′), 145.1 (C-4′′), 163.2 (C-2–COOH), 165.0 (C-8), 166.2 (C-3′′–COOH), 170.4 (CONH) [* assignments may be interchangeable]. MS: m/z = 536.2 [M + H]+; 534.0 [M – H]. Anal. Calcd for C21H17N3O8S3: C, 47.10; H, 3.20; N, 7.85. Found: C, 47.12; H, 3.18; N, 7.85.